# Product Datasheet

## TFF1/pS2 Antibody (GE2 (same as R47/94)) [DyLight 594] NBP2-34623DL594

Unit Size: 0.1 ml

Store at 4C in the dark.

www.novusbio.com technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-34623DL594

Updated 10/26/2023 v.20.1





# NBP2-34623DL594

TFF1/pS2 Antibody (GE2 (same as R47/94)) [DyLight 594]

| Product Information | |
|---|---|
| **Unit Size** | 0.1 ml |
| **Concentration** | Please see the vial label for concentration. If unlisted please contact technical services. |
| **Storage** | Store at 4C in the dark. |
| **Clonality** | Monoclonal |
| **Clone** | GE2 (same as R47/94) |
| **Preservative** | 0.05% Sodium Azide |
| **Isotype** | IgG1 Kappa |
| **Conjugate** | DyLight 594 |
| **Purity** | Protein A or G purified |
| **Buffer** | 50mM Sodium Borate |

| Product Description | |
|---|---|
| **Host** | Mouse |
| **Gene ID** | 7031 |
| **Gene Symbol** | TFF1 |
| **Species** | Human, Cynomolgus Monkey |
| **Specificity/Sensitivity** | It recognizes a polypeptide of 6.5kDa, identified as pS2 estrogen-regulated protein. Its epitope is localized between aa57-84 of human pS2 protein. pS2 is a trefoil peptide. Trefoil peptides are protease resistant molecules secreted throughout the gut that play a role in mucosal healing. These peptides contain three intra-chain disulfide bonds, forming the trefoil motif, or P-domain. pS2 is known to form dimers and this dimerization is thought to play a role in its protective and healing properties. About 60% of breast carcinomas are positive for pS2. Staining is cytoplasmic, often with localization to the Golgi apparatus. pS2 is shown to be localized in normal stomach mucosa, gastric fluid, goblet cells in the colon and small intestine, and in ulcerations of the gastrointestinal tract. Several studies have shown that pS2 is primarily expressed in estrogen receptor-positive breast tumors and it may define a subset of estrogen-dependent tumors that displays an increased likelihood of response to endocrine therapy. |
| **Immunogen** | A synthetic peptide (around aa 57-84) of human TFF1/pS2 polypeptide (exact sequence is proprietary) (Uniprot: P04155) |
| **Notes** | DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries. |

| Product Application Details | |
|---|---|
| **Applications** | Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin, CyTOF-ready |
| **Recommended Dilutions** | Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin, CyTOF-ready |
| **Application Notes** | Optimal dilution of this antibody should be experimentally determined. |

**Novus Biologicals USA**
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
novus@novusbio.com

**Bio-Techne Canada**
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

**Bio-Techne Ltd**
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

**General Contact Information**
www.novusbio.com
Technical Support: technical@novusbio.com
Orders: orders@novusbio.com
General: novus@novusbio.com

## Products Related to NBP2-34623DL594

| | |
|---|---|
| NBP1-43319DL594 | Mouse IgG1 Kappa Isotype Control (P3.6.2.8.1) [DyLight 594] |
| NBP2-35042-5ug | Recombinant Human TFF1/pS2 Protein |
| 236-EG-200 | EGF [Unconjugated] |
| DY5237 | TFF1/pS2 [Biotin] |

### Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis.
Primary Antibodies are guaranteed for 1 year from date of receipt.

**For more information on our 100% guarantee, please visit www.novusbio.com/guarantee**

**Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-34623DL594**

**Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications**